Cubist Systematic Strategies LLC Takes $708,000 Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Cubist Systematic Strategies LLC acquired a new stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 152,312 shares of the company’s stock, valued at approximately $708,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GDRX. Brevan Howard Capital Management LP bought a new stake in GoodRx in the fourth quarter worth about $148,000. Balyasny Asset Management L.P. bought a new stake in GoodRx during the 4th quarter worth approximately $870,000. BNP Paribas Financial Markets purchased a new position in GoodRx in the 4th quarter worth approximately $183,000. PDT Partners LLC purchased a new position in GoodRx in the 4th quarter worth approximately $119,000. Finally, Northern Trust Corp grew its stake in GoodRx by 13.5% in the 4th quarter. Northern Trust Corp now owns 421,810 shares of the company’s stock worth $1,961,000 after buying an additional 50,256 shares in the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Stock Performance

Shares of GDRX stock opened at $4.01 on Friday. The company’s 50-day moving average is $4.46 and its 200 day moving average is $4.69. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The company has a market capitalization of $1.54 billion, a price-to-earnings ratio of -133.67, a price-to-earnings-growth ratio of 2.46 and a beta of 1.24. GoodRx Holdings, Inc. has a one year low of $3.68 and a one year high of $9.26.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.05. The firm had revenue of $202.97 million for the quarter, compared to the consensus estimate of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.08 EPS. Sell-side analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group cut their price objective on shares of GoodRx from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, May 9th. Truist Financial decreased their price objective on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating for the company in a report on Thursday, April 10th. Wells Fargo & Company decreased their price objective on shares of GoodRx from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Tuesday, April 29th. Finally, UBS Group decreased their price target on shares of GoodRx from $6.00 to $5.25 and set a “neutral” rating for the company in a research note on Tuesday. Five research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $7.33.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.